Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study.
作者信息
Tsang Mazie, Hampel Paul J, Rabe Kari G, Brieghel Christian, Ding Wei, Leis Jose F, Hilal Talal, Kenderian Saad S, Wang Yucai, Muchtar Eli, Koehler Amber B, Van Dyke Daniel L, Hanson Curtis A, Shi Min, Slager Susan L, Kay Neil E, Hjalgrim Henrik, Niemann Carsten U, Parikh Sameer A, Rotbain Emelie C
机构信息
Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
Am J Hematol. 2025 Sep;100(9):1678-1681. doi: 10.1002/ajh.27747. Epub 2025 Jun 18.
Abstract
摘要
相似文献
1
Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation-Wide Study.≥80岁慢性淋巴细胞白血病（CLL）老年患者一线治疗的比较：梅奥诊所和丹麦全国性研究
Am J Hematol. 2025 Sep;100(9):1678-1681. doi: 10.1002/ajh.27747. Epub 2025 Jun 18.
2
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.在慢性淋巴细胞白血病一线治疗中阿卡替尼的疗效比较：系统评价和网络荟萃分析。
Clin Ther. 2020 Oct;42(10):1955-1974.e15. doi: 10.1016/j.clinthera.2020.08.017. Epub 2020 Oct 6.
3
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.老年慢性淋巴细胞白血病患者一线使用维奈克拉或布鲁顿酪氨酸激酶抑制剂停药后的真实世界治疗模式
JCO Oncol Pract. 2025 Aug;21(8):1124-1133. doi: 10.1200/OP.24.00220. Epub 2024 Dec 20.
4
Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).泽布替尼与阿卡拉布替尼治疗复发或难治性慢性淋巴细胞白血病（R/R CLL）的疗效：匹配调整间接比较（MAIC）。
Ther Adv Med Oncol. 2025 Jul 8;17:17588359251340554. doi: 10.1177/17588359251340554. eCollection 2025.
5
Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care.慢性淋巴细胞白血病的治疗进展：聚焦分子发病机制、靶向治疗及支持治疗
Am J Health Syst Pharm. 2025 Mar 11. doi: 10.1093/ajhp/zxaf058.
6
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.依鲁替尼与医生选择的治疗方案以及idelalisib联合奥法木单抗用于既往治疗的慢性淋巴细胞白血病患者的间接治疗比较
Clin Ther. 2017 Jan;39(1):178-189.e5. doi: 10.1016/j.clinthera.2016.12.001. Epub 2017 Jan 3.
7
Chronic lymphocytic leukemia: economic burden and quality of life: literature review.慢性淋巴细胞白血病：经济负担与生活质量：文献综述
Am J Ther. 2005 Sep-Oct;12(5):460-6. doi: 10.1097/01.mjt.0000104489.93653.0f.
8
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.基于分子生物学的慢性淋巴细胞白血病一线治疗：随机临床试验的网络荟萃分析。
Int J Mol Sci. 2023 Jun 9;24(12):9930. doi: 10.3390/ijms24129930.
9
Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia.在一项针对复发或难治性非霍奇金淋巴瘤和B细胞慢性淋巴细胞白血病患者的I期首次人体临床试验中，使用crenigacestat（LY3039478）抑制Notch信号通路。
Ther Adv Drug Saf. 2025 Jul 31;16:20420986241311461. doi: 10.1177/20420986241311461. eCollection 2025.
10
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.BCL-2依赖性是慢性淋巴细胞白血病治疗反应的良好预测标志物。
Mol Cancer. 2025 Mar 3;24(1):62. doi: 10.1186/s12943-025-02260-7.
本文引用的文献
1
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.伊布替尼作为 80 岁以上慢性淋巴细胞白血病患者的一线治疗：一项回顾性真实世界的意大利多中心队列研究。
Hematol Oncol. 2024 Jan;42(1):e3249. doi: 10.1002/hon.3249.
2
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.80 岁及以上慢性淋巴细胞白血病患者一线靶向药物治疗的汇总分析。
Leuk Lymphoma. 2022 Dec;63(14):3299-3306. doi: 10.1080/10428194.2022.2123223. Epub 2022 Sep 18.
3
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.80 岁及以上慢性淋巴细胞白血病患者的治疗结果。
Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.
4
Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study.呈现 80 岁或以上诊断为慢性淋巴细胞白血病患者的特征和结局。ICLLSG 研究。
Ann Hematol. 2011 Oct;90(10):1123-9. doi: 10.1007/s00277-011-1259-3. Epub 2011 May 26.
Zotero 插件